Clinical Trials: Melanoma

Birmingham : UAB Dermatology

Can We Miss Pigmented Lesions in Psoriasis Patients?

Brimingham :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Scottsdale : Mayo Clinic Arizona - Cancer Clinical Research Unit Updated

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Scottsdale : Oncology Research Associates, Pllc D/B/A

Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma

Scottsdale : TGen Clinical Research Service at Scottsdale Healthcare

Safety Study of PLX108-01 in Patients With Solid Tumors

Scottsdale : Call for Information (Investigational Site 0004)

Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM4)

Duarte : City of Hope Updated

An Exploratory Analysis of Tumor Specific T Cells in Subjects with Clinically and Histologically Diagnosed Cancer

Santa Monica : John Wayne Cancer Institute

Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma

Santa Monica : John Wayne Cancer Institute

Stage IV Surgery versus Best Medical Therapy

View More »

Duarte : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Encinitas : San Diego Pacific Oncology & Hematology Associates Updated

Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

La Jolla : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Los Angeles : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Los Angeles :

A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma

Los Angeles :

A Study of RO5185426 And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Los Angeles : Updated

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Los Angeles :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Los Angeles : University of California Los Angeles

Combination of Temozolomide and Sunitinib in Treatment of Patients With Metastatic and Unresectable Malignant Melanoma

Los Angeles : GSK Investigational Site Updated

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Los Angeles : University Of California Los Angeles

Ph I/II Ipilimumab Vemurafenib Combo

Los Angeles : The Angeles Clinic And Research Institute

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Los Angeles : University Of California Los Angeles

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Los Angeles : University of California, Los Angeles

Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma

Los Angeles : UCLA

Safety Study of PLX108-01 in Patients With Solid Tumors

Los Angeles : The Angeles Clinic and Research Institute Updated

Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

Los Angeles : Call for Information (Investigational Site 0010)

Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM4)

Los Angeles : Call for Information (Investigational Site 0015)

Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM4)

Orange : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

San Francisco : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

San Francisco :

A Study of RO5185426 And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

San Francisco :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

San Francisco : California Pacific Medical Center

Clinical Trial of Sutent to Treat Metastatic Melanoma

San Francisco : Call for Information (Investigational Site 0008)

Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM4)

San Francisco : UCSF Helen Diller Comprehensive Cancer Center

Trial of pIL-12 Electroporation Malignant Melanoma

Santa Monica : The Angeles Clinic and Research Institute

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Santa Monica : The Angeles Clinic Updated

Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma

Santa Monica :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Santa Monica : John Wayne Cancer Institute

Trial of pIL-12 Electroporation Malignant Melanoma

Aurora : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Aurora :

A Study of RO5185426 And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Aurora : Updated

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Aurora :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Aurora : University of Colorado

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

View More »

Boulder :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Colorado Springs :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Denver :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Denver : University of Colorado, Denver

Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma

Lakewood :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Littleton :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Lone Tree :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Longmont :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Parker :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Thornton :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Hamden : New England Retina Associates

Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)

New Haven : Yale Comprehensive Cancer Center

A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies

New Haven : Yale University School Of Medicine

Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

New Haven : Yale University School of Medicine, Section of Med Onc.

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Bonita Springs :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Bradenton :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Cape Coral :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Clearwater :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Englewood :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

View More »

Fort Myers :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Gainesville :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Jacksonville : Baptist Cancer Institute

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Jacksonville : Call for Information (Investigational Site 0003)

Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM4)

Jacksonville : Call for Information (Investigational Site 0002)

Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)

Lakeland : Lakeland Regional Cancer Center

Trial of pIL-12 Electroporation Malignant Melanoma

Miami Beach : Mount Sinai Medical Center

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

Naples :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

North Port :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Orlando :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Orlando : Md Anderson Cancer Center Orlando

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Orlando : MD Anderson Cancer Center-Orlando Updated

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Ormond Beach : Ameriderm Research Updated

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Palm Harbor :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Port Charlotte :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Sarasota :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Sebring :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Tampa : Novartis Investigative Site

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Tampa :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Tampa : Moffitt Cancer Center

Evaluate Safety/Tolerability Intra-Arterial Temozolomide in Patients w/Extremity Melanoma by Isolated Limb Infusion

Tampa : Moffitt Cancer Center

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Tampa : H. Lee Moffitt Cancer Center & Research Institute

Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100/MART

Tampa : H. Lee Moffitt Cancer Center and Research Institute

Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC

Tampa : Moffitt Cancer Center Cutaneous Oncology Department

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Tampa : Call for Information (Investigational Site 0018)

Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM4)

Tampa : H. Lee Moffitt Cancer Center and Research Institute

Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma

Venice :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

West Palm Beach : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Elgin : Sherman Health

ECOG E1609: Ph III Ipilimumab vs Interferon. Completely resected IIIB, IIIC & IV Melanoma.

View More »

Chicago :

A Study of RO5185426 And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Chicago : University of Chicago

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Chicago : Rush Pres St Lukes Medical Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Chicago : Northwestern Memorial Hospital

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Chicago : The University of Chicago

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Chicago : Robert H. Lurie Comprehensive Cancer Center, Northwestern University

Safety, Tolerability, and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma

Chicago : University of Chicago Updated

Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

Chicago : University of Chicago

Vaccination Plus Ontak in Patients With Metastatic Melanoma

Niles : Oncology Specialists, SC

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

Niles : Oncology Specialists, SC (OSSC) Updated

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Park Ridge : Oncology Specialists Updated

Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma

Park Ridge :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Goshen : Indiana University Health Goshen Center for Cancer Care Updated

Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma

Indianapolis : Indiana University Melvin and Bren Simon Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Indianapolis : Indiana University - Simon Cancer Center Updated

Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma

Indianapolis : Indiana University Melvin And Bren Simon Cancer Center

Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma

Indianapolis : Investigative Clinical Research of Indiana Updated

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Iowa City : University of Iowa Hospitals and Clinics

Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat

Lexington : Central Kentucky Research Associates Updated

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Louisville :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Louisville : James Graham Brown Cancer Center Updated

Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma

Louisville : University of Louisville Hospital Updated

Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

Baltimore : John Hopkins University

A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies

Baltimore : Weinberg Cancer Institution at Franklin Square Updated

Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

Bethesda : Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office

Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer

Boston : Dana-Farber Cancer Institute

A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies

Boston : Massachusetts General Hospital

A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies

Boston : Beth Israel Deaconess Medical Center

A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies

Boston : Novartis Investigative Site

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Boston : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

View More »

Boston : Updated

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Boston : Beth Israel Deaconess Medical Center

An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

Boston : Massachusetts General Hospital

An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

Boston : Dana-Farber Cancer Institute

An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

Boston :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Boston : Beth Israel Deaconess Medical Center

Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma

Boston : Dana-Farber Cancer Institute

Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma

Boston : Massachusetts General Hospital

Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma

Boston : Beth Israel Deaconess Medical Center

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Boston : Dana-Farber Cancer Institute

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Boston : Massachusetts General Hospital

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Boston : Dana-Farber Cancer Institute

Panobinostat (LBH589) in Patients With Metastatic Melanoma

Boston : Dana Farber Cancer Institute

Ph I/II Ipilimumab Vemurafenib Combo

Boston : Massachusetts Eye & Ear Infirmary

Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma

Boston : Massachusetts General Hospital Cancer Center

Safety Study of MGA271 in Refractory Cancer

Boston : Beth Israel Deaconess Medical Center

Safety Study of PLX108-01 in Patients With Solid Tumors

Boston : Dana Farber Cancer Institute

Safety Study of PLX108-01 in Patients With Solid Tumors

Boston : Massachusetts General Hospital

Safety Study of PLX108-01 in Patients With Solid Tumors

Boston : Beth Israel Deaconess Medical Center

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Boston : Dana Farber Cancer Institute

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Boston : Mass General Hospital

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Boston : Dana-Farber Cancer Institute

STA-9090 in Metastatic Ocular Melanoma

Boston : Massachusetts General Hospital

STA-9090 in Metastatic Ocular Melanoma

Boston : Dana-Farber Cancer Institute

STA-9090 in Patients With Unresectable Stage III or Stage IV Melanoma

Boston : Call for Information (Investigational Site 0011)

Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM4)

Boston : Beth Israel Deaconess Medical Center

SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

Boston : Dana-Farber Cancer Institute

SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

Boston : Massachusetts General Hospital

SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

Boston : Massachusetts General Hospital

Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors

Ann Arbor : University of Michigan Comprehensive Cancer Center, Ravitz Phase 1 Center

A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies

Detriot : Wayne State University Karmanos Cancer Institute

Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies

Detroit : Novartis Investigative Site

A Study of Oral LGK974 in Patients With Melanoma and Lobular Breast Cancer

Detroit : Updated

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Detroit :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

View More »

Detroit : Henry Ford Medical Center Updated

Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

Burnsville :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Coon Rapids :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Edina :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Fridley :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Maplewood :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

View More »

Minneapolis :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Rochester : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Rochester : Mayo Clinic Updated

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Rochester : Call for Information (Investigational Site 0002)

Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM4)

Rochester : Call for Information (Investigational Site 0005)

Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)

St.Paul :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Woodbury :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Southaven :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Kansas City : Center for Pharmaceutical Research Updated

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

St Louis : Updated

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

St. Louis : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

St. Louis :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

St. Louis : Washington University in St. Louis

SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

Lincoln : Southeast Nebraska Hematology & Oncology Consultants, Lincol Updated

Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

Omaha : University of Nebraska

Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

Henderson :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Las Vegas : Comprehensive Cancer Centers of Nevada

Culture and Characterization of Circulating Tumor Cells (CTC) in Melanoma and Other Cancers

Las Vegas : Comprehensive Cancer Centers of Nevada

Safety Study of PLX108-01 in Patients With Solid Tumors

LasVegas :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Lebanon : Updated

A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma

Lebanon :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Lebanon, : Dartmouth Hitchcock Medical Center

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Morristown :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Morristown : Atlantic Melanoma Center Updated

Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma

New Brunswick : Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School

Effects of Monoclonal Antibody GC1008 in Blood Samples From Patients With Unresectable Locally Advanced or Metastatic Kidney Cancer or Malignant Melanoma Treated on Clinical Trial NCI-06-C-0200

Princeton : GE Healthcare Office

A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis

Buffalo : Roswell Park Cancer Institute

Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1

Buffalo : Roswell Park Cancer Institute

Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies

New York : Memorial Sloan-Kettering Cancer Center

A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies

New York :

A Study of RO5185426 And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

New York : Memorial Sloan Kettering Cancer Center

Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity

View More »

New York :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

New York : Memorial Sloan Kettering Cancer Center

Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

New York : Memorial Sloan Kettering Cancer Center

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

New York : Memorial Sloan-Kettering Cancer Center

Ph I/II Ipilimumab Vemurafenib Combo

New York : Memorial Sloan-Kettering Cancer Center

RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma

New York : New York University Langone Medical Center

Safety Study of Adjuvant Vaccine to Treat Melanoma Patients

New York : Memorial Sloan Kettering Cancer Center

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

New York : Ruttenberg Cancer Clinic - The Mount Sinai Hospital

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

New York : New York University (NYU) Cancer Center

Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1

New York : Call for Information (Investigational Site 0019)

Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM4)

New York : Memorial Sloan-Kettering Cancer Center Updated

Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation

Charlotte : Updated

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Durham : Duke University Medical Center

Evaluate Safety/Tolerability Intra-Arterial Temozolomide in Patients w/Extremity Melanoma by Isolated Limb Infusion

Huntersville : Carolina BioOncology Institute Cancer Therapy and Research Center

A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies

Winston-Salem : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Cincinnati : The Christ Hospital

A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies

Cincinnati :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Cleveland : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Columbus :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Eugene :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Portland :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Portland : Providence Cancer Center

Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.

Portland : Portland Providence Medical Center

Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma

Portland : Providence Cancer Center

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

View More »

Portland : Kaiser Permanente Northwest Updated

Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

Portland : Oregon Health and Science University

Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

Springfield :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Tualatin :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Bethlehem : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Bethlehem :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Philadelphia :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Philadelphia : Thomas Jefferson University

Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma

Philadelphia : Hospital of the University of Pennsylvania/Abramson Cancer Center

Safety Study of MGA271 in Refractory Cancer

View More »

Philadelphia : Pennsylvania Oncology Hematology Associates

Safety Study of PLX108-01 in Patients With Solid Tumors

Philadelphia : University of Pennsylvania

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Philadelphia : Call for Information (Investigational Site 0016)

Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM4)

Philadelphia : Fox Chase Cancer Center

Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma

Pittsburgh : University of Pittsburgh Medical Center/University of Pittsburgh Cancer Institute

Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma

Pittsburgh : Hillman Cancer Center

Melanoma Molecular Profiling Analysis

Pittsburgh : UPMC Hillman Cancer Center

Pilot Study of IFN α2b for Melanoma Patients

Pittsburgh : University of Pittsburgh Medical Center

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Pittsburgh : University of Pittsburgh

Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

Pittsburgh : Call for Information (Investigational Site 0013)

Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM4)

Charleston : Updated

A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma

Bartlett :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Franklin :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Gallatin :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Germantown :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Hermitage :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

View More »

Lebanon :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Memphis :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Memphis : St. Jude Children's Research Hospital

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

Murfreesboro :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Nashville : Vanderbilt-Ingram Cancer Center

A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies

Nashville : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Nashville : Sarah Cannon Research Institute Updated

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Nashville :

A Study of RO5185426 And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Nashville :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Nashville : Vanderbilt University

IDO Inhibitor Study for Relapsed or Refractory Solid Tumors

Nashville : Sarah Cannon Research Institute

Safety Study of MGA271 in Refractory Cancer

Nashville : Vanderbilt-Ingram Medical Center

Safety Study of PLX108-01 in Patients With Solid Tumors

Nashville : Vanderbilt University Medical Center

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Nashville : Vanderbilt University

SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

Nashville : Sarah Cannon Research Institute

Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors

Smyrna :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Amarillo : Don and Sybil Harrington Cancer Center Updated

Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

Bedford :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Dallas :

A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma

Dallas : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Dallas : Mary Crowley Cancer Research Centers - Medical City Updated

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

View More »

Dallas : Mary Crowley Cancer Research Centers

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

Dallas :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Dallas : Mary Crowley Cancer Research Centers Updated

Phase II FANG in Advanced Melanoma

Dallas : Mary Crowley Cancer Research Center Updated

Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma

Dallas : Texas Oncology, PA (North)

Safety Study of PLX108-01 in Patients With Solid Tumors

Dallas : Baylor Univesity Medical Center

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Dallas : Research Across America Updated

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Dallas : Mary Crowley Cancer Research Center

Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

Grapevine :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Houston :

A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma

Houston : UT MD Anderson Cancer Center

A Phase I/II Study of TPI 287 - Temozolomide Combination in Melanoma

Houston :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Houston : UT MD Anderson Cancer Center

Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma

Houston : The University of Texas MD Anderson Cancer Center

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization

Houston : The Children's Cancer Hospital at UT M.D. Anderson Cancer Center

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

Houston : UT MD Anderson Cancer Center

Phase II Study of Tesetaxel in Metastatic Melanoma

Houston : University of Texas M.D. Anderson Cancer Center

Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma

Houston : University of Texas MD Anderson Cancer Center

Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma

Houston : Call for Information (Investigational Site 0012)

Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM4)

Houston : Call for Information (Investigational Site 0001)

Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)

Houston : UT MD Anderson Cancer Center

Study of Weekly LOC-paclitaxel Injection for Melanoma

Houston : The University of Texas MD Anderson Cancer Center

Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH

Houston : UT MD Anderson Cancer Center

Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma

San Antonio : South Texas Accelerated Research Therapeutics (START)

A Study of PNT2258 in Patients With Advanced Solid Tumors

San Antonio : Call for Information (Investigational Site 0001)

Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM4)

San Antonio : The START Center

Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma

San Antonio : Veterans Affairs at UTHSCSA

Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

San Antonio : Cancer Therapy & Research Center at UTHSCSA

Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

Salt Lake City : Huntsman Cancer Institute

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

Arlington :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Charlottesville : University of Virginia Health System Updated

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Charlottesville : University of Virginia Health System / Human Immune Therapy Center

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Charlottesville : University of Virginia

Study to Assess the Safety and Immunological Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI

Fairfax :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

View More »

Gainesville :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Leesburg :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Norfolk : Clinical Research Associates of Tidewater Updated

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Winchester :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Woodbridge :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Tacoma : Comprehensive Clinical Development, Tacoma

Adults with BRAF mutation-positive tumor determined via relevant genetic testing

View More »

Seattle : Updated

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Seattle : Seattle Cancer Care Alliance

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Seattle : Seattle Cancer Care Alliance

Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma

Spokane : Evergreen Hematology & Oncology

Safety Study of PLX108-01 in Patients With Solid Tumors

Vancouver :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Madison :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Madison : University of Wisconsin Hospitals and Clinics

Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma

Buenos Aires : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Buenos Aires : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Adelaide : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Adelaide :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Adelaide : Local Institution

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Adelaide : Royal Adelaide Hospital

Proteasome Inhibitor NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma

Coffs Harbour : Local Institution

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

View More »

East Melbourne : Novartis Investigative Site

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

East Melbourne : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Heidelberg : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Kogarah, Sydney : Cancer Care Centre, St George Hospital

Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers

Malvern :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Melbourne :

A Study of RO5185426 And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Melbourne : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Melbourne : Updated

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Nedlands : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Nedlands : Sir Charles Gairdner Hospital and University of Western Australia

Proteasome Inhibitor NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma

Newcastle :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

North Sydney : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

North Sydney :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Perth :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Redcliffe : Redcliffe Hospital

Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers

South Granville : Merck Sharp & Dohme (Australia) Pty Ltd.

Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM4)

Westmead : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Westmead :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Woodville South : The Queen Elizabeth Hospital

Proteasome Inhibitor NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma

Woolloongabba : GSK Investigational Site

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

Feldkirch : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Graz : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Graz : Universitätsklinik Graz

Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma

Graz : Universitätsklinik Graz

Intratumoral Application of L19IL2 in Patients With Malignant Melanoma

Innsbruck : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

View More »

Linz : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Linz : Local Institution

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Salzburg : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

St. Pölten : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Vienna : Local Institution

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Wien : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Antwerp : Universitair Ziekenhuis Antwerpen

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Brussels : Jules Bordet Institute

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Brussels : Local Institution

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Brussels : Cliniques universitaires Saint-Luc, Centre du Cancer

Safety and Toxicity Study of Vaccination for Advanced Metastatic Melanoma Patients

Bruxelles : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

View More »

Bruxelles : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Bruxelles : Local Institution

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Jette : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Leuven : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Wilrijk : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Belo Horizonte : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Porto Alegre : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Rio de Janeiro : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Salvador : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Sao Paulo : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

View More »

São Paulo : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Plovdiv : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Sofia : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Edmonton : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Edmonton : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Halifax : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Hamilton : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

London : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

View More »

Montreal : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Montreal : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Ottawa : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Quebec : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Quebec City : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Toronto : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Toronto : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Toronto : Updated

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Vancouver : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Winnipeg : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Beijing : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Bogota : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Cali : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Zagreb : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Brno : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Brno : GSK Investigational Site Updated

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Hradec Kralove : GSK Investigational Site Updated

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Olomouc : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Ostrava : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

View More »

Praha : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Praha 2 : GSK Investigational Site Updated

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Aarhus : Local Institution

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Herlev : Local Institution

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Herlev : Copenhagen University Hospital Herlev Updated

Safety and Efficacy Study of Electrotransfer of Plasmid AMEP to Treat Advanced or Metastatic Melanoma

Odense : Local Institution

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Tallin : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Tallinn : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Tartu : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Helsinki : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Bordeaux : Local Institution

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Boulogne-Billancourt : Hôpital Ambroise Paré

DNA Repair Inhibitor & Irradiation on Melanoma

Dijon : GSK Investigational Site Updated

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Dijon Cedex : Local Institution

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Kremlin Bicetre : Gustave Roussy Institute Updated

Safety and Efficacy Study of Electrotransfer of Plasmid AMEP to Treat Advanced or Metastatic Melanoma

View More »

Lille : Centre Oscar Lambret

DNA Repair Inhibitor & Irradiation on Melanoma

Lille : GSK Investigational Site Updated

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Lille : GSK Investigational Site Updated

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Lille : Local Institution

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Marseille : Hôpital de la Timone

DNA Repair Inhibitor & Irradiation on Melanoma

Marseille : Hôpital Sainte Marguerite

Masitinib in Patients With Non-resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-kit

Marseille : Local Institution

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Marseille Cedex 5 : GSK Investigational Site Updated

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Montpellier : GSK Investigational Site Updated

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Nantes : GSK Investigational Site Updated

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Nantes : GSK Investigational Site Updated

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Nantes Cedex 1 : Local Institution

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Paris : Updated

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Paris : Hôpital Saint-Louis

DNA Repair Inhibitor & Irradiation on Melanoma

Paris : Institut Curie

DNA Repair Inhibitor & Irradiation on Melanoma

Paris : Local Institution

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Paris : Novartis Investigative Site

Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients

Rennes : Centre Eugène Marquis

cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project

Rennes : Rennes University Hospital

cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project

Rennes : GSK Investigational Site Updated

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Toulouse Cedex 3 : Novartis Investigative Site

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Toulouse Cedex 9 : Local Institution

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Villejuif : Local Institution

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Villejuif Cedex : Novartis Investigative Site

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Aachen : Dept of Dermatology, University of Aachen

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Augsburg : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Berlin : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Berlin : Charité- Universitätsmedizin Berlin

Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma

Berlin : Dept of Dermatology, University of Berlin Charite

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

View More »

Berlin : GSK Investigational Site Updated

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Bochum : Dept of Dermatology, University of Bochum

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Bonn : Neurologische Universitaetsklinik Bonn

A Clinical Trial to Assess the Safety & Efficacy of the Treatment of Patients With Metastasis From Malignant Melanoma - Treatment Consists of the Substances Lomustine (Capsules) & Cytarabine (Injected Into an Area Near the Spinal Cord), Accompanied by Radiotherapy of the Brain

Bonn : Medizinisches Zentrum Bonn Friedensplatz

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Buxtehude : Local Institution

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Erlangen : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Essen : Novartis Investigative Site

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Essen : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Essen : Updated

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Essen :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Essen : Dept of Dermatology, University of Essen

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Essen : GSK Investigational Site Updated

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Essen : Local Institution

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Frankfurt / Main : Dept of Dermatology, University of Frankfurt

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Frankfurt/Oder : Dermatology, Klinikum Frankfurt/Oder

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Freiburg : GSK Investigational Site Updated

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Freiburg : University Medical Center Freiburg, Department of Dermatology

Quality of Life and Psychological Well-being in Patients With Malignant Melanoma

Hannover : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Hannover :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Hannover : Dept of Dermatology, University of Hannover

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Hannover : GSK Investigational Site Updated

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Hannover : GSK Investigational Site Updated

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Hannover : Medizinischen Hochschule Hannover

Intratumoral Application of L19IL2 in Patients With Malignant Melanoma

Hannover : Local Institution

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Heidelberg : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Heidelberg :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Heidelberg : Local Institution

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Homburg : GSK Investigational Site Updated

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Homburg/Saar : Dept of Dermatology, Saarland University

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Jena : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Jena :

A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)

Jena : Dept of Dermatology, University of Jena

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Jena : GSK Investigational Site Updated

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Kiel : Novartis Investigative Site

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Kiel : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Kiel : Updated

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Kiel :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Kiel : Universitätsklinikum Schleswig-Holstein-Campus Kiel

Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma

Kiel : Dept of Dermatology, University of Schleswig-Holstein Campus Kiel

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Kiel : GSK Investigational Site Updated

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Kiel : GSK Investigational Site Updated

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Kiel : Local Institution

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Koeln : GSK Investigational Site Updated

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Köln : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Köln : University Medical Center Collogne, Department of Dermatology

Quality of Life and Psychological Well-being in Patients With Malignant Melanoma

Ludwigshafen : Dermatology, Klinikum Ludwishafen

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Luebeck : Dept of Dermatology, University of Schleswig-Holstein Campus Luebeck

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Luebeck : GSK Investigational Site Updated

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Magdeburg : Dept of Dermatology, Univeristy of Magdeburg

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Mainz : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Mainz :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Mainz : Dept of Dermatology, University of Mainz

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Mainz : GSK Investigational Site Updated

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Mainz : Local Institution

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Mannheim : Dept of Dermatology, University of Mannheim

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Mannheim : GSK Investigational Site Updated

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Mannheim : GSK Investigational Site Updated

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Marburg : Dept of Dermatology, University of Marburg

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Muenchen : Novartis Investigative Site

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Muenchen : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Muenchen : Dept of Dermatology, University of Muenchen

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Muenster : Dept of Dermatology, University of Muenster

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Muenster : Dept of Medical Oncology, Fachklinik Hornheide

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Nuernberg : GSK Investigational Site Updated

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Quedlinburg : Dermatology, Klinikum Dorothea Christiane Erxleben

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Regensburg : GSK Investigational Site Updated

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Tubingen :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Tubingen : Local Institution

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Tübingen : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Tübingen : Updated

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Tuebingen : University Hospital

Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma

Tuebingen : Dept of Dermatology, University of Tuebingen

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Tuebingen : GSK Investigational Site Updated

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Tuebingen : GSK Investigational Site Updated

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Tuebingen : University Hospital

Intratumoral Application of L19IL2 in Patients With Malignant Melanoma

Wuerzburg : Dept of Dermatology, University of Wuerzburg

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Wuerzburg : GSK Investigational Site Updated

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Athens : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Heraklion : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Budapest : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Debrecen : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Pecs : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Szeged : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Jerusalem : Oncology institute, Shaare Zedek Medical Center

IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma

Jerusalem : Hadassah Medical Center

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Tel Hashomer : Ella Institute, Oncology institute, Sheba Medical Center

IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma

Tel Hashomer : Oncology Institute, Sheba Medical Center

IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma

Tel Hashomer : Chaim Sheba Medical Center

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Ancona : A.O. UNIVERSITARIA OSPEDALI RIUNITI - OSPEDALE UMBERTO I DI ANCONA - ANCONA (AN) (Italy)

Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma

Bari : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Bari : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Bergamo : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Faenza : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

View More »

Genova : Novartis Investigative Site

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Genova : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Genova : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Genova : GSK Investigational Site Updated

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Lugo : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Meldola : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Meldola : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Meldola (FC) : GSK Investigational Site Updated

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Milan : European Istitue of Oncology

Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma

Milano : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Milano : Updated

A Study of Avastin (Bevacizumab) in Combination With Dacarbazine in Patients With Unresectable/Metastatic Melanoma.

Milano : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Milano : GSK Investigational Site

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

Milano : GSK Investigational Site Updated

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Milano : GSK Investigational Site Updated

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Napoli : Novartis Investigative Site

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Napoli : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Napoli : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Napoli : Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale Di Napoli

Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma

Napoli : GSK Investigational Site Updated

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Napoli : Local Institution

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Padova : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Padova : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Padova : GSK Investigational Site Updated

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Padova : Local Institution

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Pisa : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Pisa : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Pisa : University Hospital Pisa

Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma

Ravenna : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Rimini : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Roma : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Roma : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Rozzano (MI) : GSK Investigational Site Updated

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Siena : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Siena : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Siena : Updated

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Siena : Azienda Ospedaliera Universitaria Senese

Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma

Siena : GSK Investigational Site

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

Siena : GSK Investigational Site Updated

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Siena : Local Institution

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Udine : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Seoul : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Daugavpils : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Riga : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Klaipeda : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Vilnius : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Skopje : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Leon, Guanajato : Local Institution

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Mexico City : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Amsterdam : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Amsterdam : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Amsterdam : Vrije Universiteit medisch centrum (Vumc)

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Amsterdam : Antoni van Leeuwenhoek Ziekenhuis

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Amsterdam : GSK Investigational Site

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

View More »

Breda : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Leiden : Leids Universitair Medisch Centrum (LUMC)

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Leiden : Novartis Investigative Site

Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients

Maastricht : GSK Investigational Site

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

Nijmegen : Novartis Investigative Site

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Nijmegen : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Nijmegen : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Rotterdam : Novartis Investigative Site

A Study of Oral LGK974 in Patients With Melanoma and Lobular Breast Cancer

Rotterdam : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Rotterdam : Erasmus MC

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Rotterdam : GSK Investigational Site

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

Bergen : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Oslo : Novartis Investigative Site

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Oslo : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Krakow : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Poznan : WCO (Great Poland Cancer Centre)

Safety and Pharmacodynamic Study of a New Formulation, AGI - 101H Vaccine in the Treatment of Advanced Melanoma

Lisboa : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Porto : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Chelyabinsk : GSK Investigational Site Updated

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Krasnodar : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Moscow : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Moscow : GSK Investigational Site Updated

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Pyatigorsk : GSK Investigational Site Updated

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

View More »

St Petersburg : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

St. Petersburg : GSK Investigational Site Updated

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Stavropol : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

UFA : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Bratislava : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Poprad : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Ljubljana : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Ljubljana : Institute of Oncology Ljubljana Updated

Safety and Efficacy Study of Electrotransfer of Plasmid AMEP to Treat Advanced or Metastatic Melanoma

Johannesburg : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Sandton : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Barcelona : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Barcelona : Novartis Investigative Site

A Study of Oral LGK974 in Patients With Melanoma and Lobular Breast Cancer

Barcelona : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Barcelona : Updated

A Study of RO5212054 (PLX3603) in Patients With BRAF V600-mutated Advanced Solid Tumours

Barcelona : Updated

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

View More »

Barcelona : Local Institution

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Cordoba : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Granada : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Hospitalet de LLobregat : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

La Coruna : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

La Laguna (tenerife) : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Las Palmas de Gran Canaria : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Madrid : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Malaga : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Málaga : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Navarra : Local Institution

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Palma de Mallorca : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Pamplona : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Pamplona : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Santander : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Sevilla : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Valencia : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Valencia : Local Institution

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Zaragoza : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Goteborg : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Gothenberg : Local Institution

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Lund : Local Institution

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Lund : Lunds Universitetssjukhus

SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma

Malmö : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

View More »

Stockholm : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Stockholm : Karolinska Sjukhuset

SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma

Stockholm : Södersjukhuset

SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma

Umea : Local Institution

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Umeå : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Umeå : Norrlands Universitetssjukhus

SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma

Uppsala : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Chur : Novartis Investigative Site

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Lausanne : Multidisciplinary Oncology Center, CHUV

Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients

Zuerich : Novartis Investigative Site

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Zürich : Novartis Investigative Site

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Zürich : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

View More »

Zürich : Universitäts Spital Zürich

Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma

Zürich : GSK Investigational Site

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

Bangkok : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Songkla : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Gaziantep : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Birmingham : Queen Elizabeth Hospital

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

Cambridge : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Cambridge : Cambridge University Hospitals NHS Foundation Trust

HYPAZ: Hypertension Induced by Pazopanib

Cambridge : Addenbrooke's Hospital

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

Glasgow : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

View More »

Glasgow :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Glasgow : The Beatson Institute

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

Leeds : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Leeds : St James' Institute of Oncology

Study of a DNA Immunotherapy to Treat Melanoma

Leeds : St James Hospital

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

Leicester : GSK Investigational Site

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

London : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

London : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

London :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

London : Novartis Investigative Site

Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients

Manchester : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Manchester : Christie Hospital

Study of a DNA Immunotherapy to Treat Melanoma

Newcastle Upon Tyne : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Newcastle-upon-Tyne : Northern Centre for Cancer Care, Freeman Hospital

Study of a DNA Immunotherapy to Treat Melanoma

Northwood : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Northwood : Updated

A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Nottingham : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Nottingham :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Nottingham : Department of Clinical Oncology, City Hospital

Study of a DNA Immunotherapy to Treat Melanoma

Oxford : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Oxford : NIHR Biomedical Research Centre

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

Southampton : Department of Medical Oncology, Southampton General Hospital

Study of a DNA Immunotherapy to Treat Melanoma

Surrey :

An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Swansea : Updated

A Study of RO5185426 in Patients With Metastatic Melanoma

Wirral : Clatterbridge Centre for Oncology NHS Foundation Trust

A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma

Washington : MedStar Clinical Research Ctr at Washington Hospital Center Updated

Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma